Tadatoshi Takayama

27.9k total citations · 8 hit papers
492 papers, 18.6k citations indexed

About

Tadatoshi Takayama is a scholar working on Hepatology, Surgery and Epidemiology. According to data from OpenAlex, Tadatoshi Takayama has authored 492 papers receiving a total of 18.6k indexed citations (citations by other indexed papers that have themselves been cited), including 249 papers in Hepatology, 240 papers in Surgery and 153 papers in Epidemiology. Recurrent topics in Tadatoshi Takayama's work include Hepatocellular Carcinoma Treatment and Prognosis (196 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (115 papers) and Liver Disease Diagnosis and Treatment (105 papers). Tadatoshi Takayama is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (196 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (115 papers) and Liver Disease Diagnosis and Treatment (105 papers). Tadatoshi Takayama collaborates with scholars based in Japan, United States and Italy. Tadatoshi Takayama's co-authors include Masatoshi Makuuchi, Tomoo Kosuge, Masami Minagawa, Norihiro Kokudo, Yutaka Matsuyama, Hiroshi Imamura, Seiji Kawasaki, Yasuhiko Sugawara, Michiie Sakamoto and Kiyoshi Hasegawa and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Tadatoshi Takayama

466 papers receiving 18.1k citations

Hit Papers

Risk factors contributing to early and late phase intrahe... 1993 2026 2004 2015 2003 2015 2000 1993 2005 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy
    2003 1.2k citations Hiroshi Imamura, Yutaka Matsuyama et al. profile →
  2. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
    2015 771 citations Tadatoshi Takayama, Masatoshi Kudo et al. profile →
  3. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial
    2000 688 citations Tadatoshi Takayama, Masatoshi Makuuchi et al. profile →
  4. Surgery for small liver cancers
    1993 641 citations Masatoshi Makuuchi, Tadatoshi Takayama et al. profile →
  5. Prognostic Impact of Anatomic Resection for Hepatocellular Carcinoma
    2005 516 citations Kiyoshi Hasegawa, Norihiro Kokudo et al. Annals of Surgery profile →
  6. Extension of the Frontiers of Surgical Indications in the Treatment of Liver Metastases From Colorectal Cancer
    2000 513 citations Masami Minagawa, Masatoshi Makuuchi et al. Annals of Surgery profile →
  7. A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers
    2013 356 citations Norihiro Kokudo, Tadatoshi Takayama et al. Annals of Surgery profile →
  8. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion
    2016 335 citations Takashi Kokudo, Kiyoshi Hasegawa et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tadatoshi Takayama Japan 65 12.2k 7.8k 6.3k 5.1k 3.2k 492 18.6k
Myron Schwartz United States 77 12.9k 1.1× 7.4k 1.0× 6.9k 1.1× 3.9k 0.8× 3.0k 1.0× 328 20.9k
Wan Yee Lau China 65 10.8k 0.9× 8.0k 1.0× 5.7k 0.9× 5.4k 1.1× 4.3k 1.3× 440 19.1k
Ken Shirabe Japan 62 8.2k 0.7× 6.7k 0.9× 4.8k 0.8× 4.8k 1.0× 2.8k 0.9× 859 17.4k
P. Neuhaus Germany 59 8.4k 0.7× 9.3k 1.2× 6.1k 1.0× 5.0k 1.0× 3.2k 1.0× 596 18.0k
Sheung Tat Fan Hong Kong 79 9.6k 0.8× 7.0k 0.9× 5.1k 0.8× 5.5k 1.1× 2.6k 0.8× 356 20.5k
Julie K. Heimbach United States 59 12.4k 1.0× 8.5k 1.1× 8.3k 1.3× 2.9k 0.6× 3.4k 1.1× 230 19.0k
Chung Mau Lo Hong Kong 65 8.5k 0.7× 6.6k 0.8× 4.4k 0.7× 3.3k 0.7× 2.0k 0.6× 341 15.0k
Akinobu Taketomi Japan 60 6.2k 0.5× 5.6k 0.7× 3.5k 0.6× 3.1k 0.6× 1.9k 0.6× 634 13.1k
Luigi Bolondi Italy 66 12.4k 1.0× 4.1k 0.5× 8.4k 1.3× 2.1k 0.4× 2.2k 0.7× 278 18.4k
Osamu Yokosuka Japan 63 11.6k 1.0× 2.9k 0.4× 10.5k 1.7× 2.9k 0.6× 1.8k 0.6× 668 19.0k

Countries citing papers authored by Tadatoshi Takayama

Since Specialization
Citations

This map shows the geographic impact of Tadatoshi Takayama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tadatoshi Takayama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tadatoshi Takayama more than expected).

Fields of papers citing papers by Tadatoshi Takayama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tadatoshi Takayama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tadatoshi Takayama. The network helps show where Tadatoshi Takayama may publish in the future.

Co-authorship network of co-authors of Tadatoshi Takayama

This figure shows the co-authorship network connecting the top 25 collaborators of Tadatoshi Takayama. A scholar is included among the top collaborators of Tadatoshi Takayama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tadatoshi Takayama. Tadatoshi Takayama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Aramaki, Osamu, Yutaka Midorikawa, Tokio Higaki, et al.. (2020). Impact of marginal resection for hepatocellular carcinoma. Surgery Today. 50(11). 1471–1479. 8 indexed citations
5.
Takagi, Keiko, Yutaka Midorikawa, Tadatoshi Takayama, et al.. (2020). Effects of Pyrrole-Imidazole Polyamides Targeting Human TGF-β1 on the Malignant Phenotypes of Liver Cancer Cells. Molecules. 25(12). 2883–2883. 4 indexed citations
6.
Midorikawa, Yutaka, Shogo Yamamoto, Kenji Tatsuno, et al.. (2020). Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression. Cancer Research. 80(18). 3810–3819. 22 indexed citations
7.
Tatsuno, Kenji, Yutaka Midorikawa, Tadatoshi Takayama, et al.. (2019). Impact of AAV2 and Hepatitis B Virus Integration Into Genome on Development of Hepatocellular Carcinoma in Patients with Prior Hepatitis B Virus Infection. Clinical Cancer Research. 25(20). 6217–6227. 26 indexed citations
8.
Aoki, Taku, Keiichi Kubota, Kiyoshi Hasegawa, et al.. (2019). Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma. British journal of surgery. 107(1). 113–120. 59 indexed citations
9.
Hiraoka, Atsushi, Kojiro Michitaka, Takashi Kumada, et al.. (2019). Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. Liver Cancer. 8(5). 403–411. 27 indexed citations
10.
Yamaguchi, Hiromi, Kazumichi Kuroda, Masahiko Sugitani, et al.. (2017). Transglutaminase 2 is upregulated in primary hepatocellular carcinoma with early recurrence as determined by proteomic profiles. International Journal of Oncology. 50(5). 1749–1759. 15 indexed citations
11.
Takayasu, Kenichi, Shigeki Arii, Michiie Sakamoto, et al.. (2017). Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting. Liver International. 38(3). 484–493. 30 indexed citations
12.
Kochi, Mitsugu, et al.. (2013). Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes. Diagnostic Pathology. 8(1). 191–191. 32 indexed citations
13.
Sawada, Yu, Toshiaki Yoshikawa, Daisuke Nobuoka, et al.. (2012). Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival. Clinical Cancer Research. 18(13). 3686–3696. 251 indexed citations
14.
Takayama, Tadatoshi, Hideki Masuda, Mitsugu Kochi, et al.. (2008). Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction in Patients With Gastric Cancer. Annals of Surgery. 247(5). 766–770. 53 indexed citations
15.
Aramaki, Osamu, Yasuhiko Sugawara, Norihiro Kokudo, Tadatoshi Takayama, & Masatoshi Makuuchi. (2006). Branch Patch Reconstruction in Living Donor Liver Transplantation: Arterialization of Grafts with Replaced Type Arteries. Transplantation. 82(11). 1541–1543. 14 indexed citations
16.
Nakayama, Hisashi, Tadatoshi Takayama, & Akihiro Hemmi. (2005). Postoperative complications of hepatectomy for hepatocellular carcinoma in relation to liver fibrosis.. PubMed. 52(62). 587–90. 2 indexed citations
17.
Minagawa, Masami, Masatoshi Makuuchi, Tadatoshi Takayama, & Norihiro Kokudo. (2003). Selection Criteria for Repeat Hepatectomy in Patients With Recurrent Hepatocellular Carcinoma. Annals of Surgery. 238(5). 703–710. 352 indexed citations
18.
Ijichi, Masayoshi, Masatoshi Makuuchi, Hiroshi Imamura, & Tadatoshi Takayama. (2001). Portal embolization relieves persistent jaundice after complete biliary drainage. Surgery. 130(1). 116–118. 29 indexed citations
19.
Hui, Ai‐Min, Ya-Zhou Shi, Xin Li, Tadatoshi Takayama, & Masatoshi Makuuchi. (2000). Loss of p16INK4 protein, alone and together with loss of retinoblastoma protein, correlate with hepatocellular carcinoma progression. Cancer Letters. 154(1). 93–99. 25 indexed citations
20.
Sato, Takeshi, et al.. (1984). Fundamental and clinical studies on lenampicillin (kbt-1585) in the surgical field. Chemotherapy. 32(8). 416–427. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Myron Schwartz Breakdown of academic impact, for papers by Wan Yee Lau Breakdown of academic impact, for papers by Ken Shirabe Breakdown of academic impact, for papers by P. Neuhaus Breakdown of academic impact, for papers by Sheung Tat Fan Breakdown of academic impact, for papers by Julie K. Heimbach Breakdown of academic impact, for papers by Chung Mau Lo Breakdown of academic impact, for papers by Akinobu Taketomi Breakdown of academic impact, for papers by Luigi Bolondi Breakdown of academic impact, for papers by Osamu Yokosuka
Rankless by CCL
2026